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Abstract
Background: Acquired immunodeficiency syndrome (AIDS) is caused by the Human immunodeficiency virus type-
1 (HIV-1). HIV-1 protease (HIV-1 PR) is an essential enzyme for the HIV replication, and therefore, it is an important
target for antiretroviral drugs development, particularly from natural products. Auricularia polytricha (AP) is an edible
mushroom with several important therapeutic properties. These properties will be investigated as HIV-1 PR
inhibitors.
Methods: The sequential hexane (APH), ethanol (APE) and water (APW) extracts from AP were screened for
inhibitory activity against HIV-1 PR. The extract that consistently showed the strong HIV-1 PR inhibition was further
investigated for its phytochemical constituents. The compounds were purified by column chromatography. The
isolated compounds were structurally elucidated using 1D and 2D NMR, HRMS, FTIR, and GC/MS techniques. Each
compound was screened against HIV-1 PR to determine its inhibitory activity and to provide an explanation for the
activity found in the extract.
Results: Hexane crude extract of AP (APH) exhibited significant inhibition on HIV-1 PR activity. Four major
compounds isolated from APH fraction were identified to be two triacylglycerols, linoleic acid and ergosterol.
Moreover, all four compounds showed significant inhibition of HIV-1 PR activity.
Conclusion: The findings from this study suggest that AP is a good source of fatty esters, fatty acids and ergosterol.
These natural products exhibit anti-HIV-1 properties by blocking HIV-1 PR. These important biological results warrant
further development of AP as an alternative antiretroviral drug.
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Background
Human immunodeficiency virus (HIV) is classified into
two types: HIV-1 and HIV-2. The HIV-1 is more viru-
lent and transmissible HIV-2 [1, 2]. HIV-1 protease
(HIV-1 PR) is an essential enzyme required by the virus
for replication. In HIV-1 life cycle, HIV-1 PR plays a role
in viral maturation step by cleaving Gag and Gag-Pol
polyproteins to structural proteins such as matrix, capsid
(p24), nucleocapsid and viral enzymes. At present, many
HIV-1 PR inhibitors are available; however, these drugs
have adverse side effects [3, 4] and have become ineffect-
ive due to drug-resistant [5] and Hence, searching for
novel inhibitors from food sources is an innovative ap-
proach to combat HIV.
Auricularia polytricha (AP) is an edible mushroom
that has been reported to have several therapeutic prop-
erties such as anti-proliferative [6], anti-oxidant [7, 8]
and hypoglycemic activities [9]. The alcoholic and di-
chloromethane extracts of AP [10, 11] were reported to
contain few phenolic compounds and triterpenoids such
as cerevistrol. Oleanolic acid, uvaol, ursolic acid, masli-
nic acid and 2α, 19α-dihydroxy-3-oxo-12-ursen-28-oic
acid are triterpenoids. These compounds were also
found in other natural sources, and are known to inhibit
HIV-1 PR [12–14]. In the case of AP, the anti-HIV-1
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activity of its extracts or isolated phytochemicals is un-
known. Due to its non-toxicity, phytochemicals and
therapeutic properties, further investigation and develop-
ment of AP as HIV-1 PR inhibitor are warranted. The
findings could provide useful insight for antiretroviral
drugs development and value-added to this mushroom.
Methods
Mushroom species verification
AP fruiting bodies were collected from a Chang Daeng
mushroom farm in Prapradaeng, Samutprakarn,
Thailand. The identity of the mushroom was confirmed
by the DNA sequence similarity of the internal tran-
scribed spacer (ITS) region of ribosomal RNA [15].
DNA was extracted using the method reported by
Luangsuphabool et al. [16]. The extracted DNA was sub-
mitted to Bioneer sequencing service (Bioneer Corpor-
ation, Korea) [17] for polymerase chain reaction (PCR)
amplification using primer pair ITS1/ITS4, then analyse
the DNA sequence. The mushroom species was identi-
fied by comparing nucleotide sequences database on
GenBank.
Crude extracts preparation
The sun-dried A. polytricha (AP) was grounded into a
powder. Macerations were performed in sequential steps
to provide the three crude extracts. AP powder (1 kg)
was first macerated twice with hexane (10 L) in an incu-
bator shaker at 225 rpm, at room temperature for 72 h.
The combined hexane layers were filtered, and the solv-
ent was evaporated under reduced pressure at 40 °C to
give a crude hexane extract (APH) as a thick yellow
paste (3.90 g). The dry residue from step 1 was extracted
twice with ethanol (10 L) under the same conditions to
give the crude ethanol extract (APE) as a dark purple
thick paste (4.74 g). Lastly, the dry residue from step 2
was extracted with water (10 L) with stirring at 4 °C for
72 h. The combined water extracts were filtered, and
water was removed by freeze-drying to give crude water
extract (APW) as a thick brown paste (19.88 g).
HIV-1 protease inhibitor assay
AP extracts (1 mg/ml) were evaluated using HIV-1 Pro-
tease Inhibitor Screening Kit (Fluorometric) (Biovision
Incorporated, CA, USA). Pepstatin (1 mM) and DMSO
(1%, v/v) were used as a positive control and solvent
control, respectively. The assay was performed according
to the manufacturer’s instruction. Then the HIV-1 pro-
tease fluorescent substrate was added and measured
fluorescence (Excitation/Emission = 330/450 nm) in a
kinetic-mode for 90 min at 37 °C using PerkinElmer
EnSpire plate reader.
Cell culture
3 T3-L1 cells, normal mouse fibroblasts were maintained
in DMEM supplemented with 10% (v/v) BCS at 37 °C in
a humidified incubator with 5% of CO2.
Cytotoxicity assay
All extracts and their identified compounds were tested
for toxicity on 3 T3-L1 cells by MTT method. The ex-
tracts were dissolved in 0.1% (v/v) of dimethyl sulfoxide
(DMSO) at varying concentrations (0.03–1.00 mg/mL).
The 3 T3-L1 cells (5 × 103 cells, 100 μl) were seeded in
each well of 96-well plate overnight to let the cell settle
on the plate. Then the cells were treated with the com-
pounds (100 μl) for 24, 48 and 72 h. The DMSO at 0.1%
(v/v) and the untreated cell conditions were used as ve-
hicle control and normal control, respectively. At the
end of each incubation periods, MTT reagent (20 μl)
was added. After 3 hours of incubation, the supernatant
was removed then the water-insoluble formazan was dis-
solved in DMSO (150 μl). The absorbance of the con-
verted dye was measured at a wavelength of 570 nm.
The results were reported in CC50 values, calculated by
standard curve analysis of four parameters logistic in
Sigma plot 12 software.
Statistical analysis
All experiments were performed in triplicates for each
condition. The results were presented as the mean with
the standard error of the mean (mean ± SEM) of three
independent experiments. Statistic significant was ana-
lysed using one-way ANOVA following Dunnett’s test
by SPSS 16.0 software. The P values less than 0.05 were
considered statistically significant.
Purification of APH fraction
APH crude extract was analysed using TLC silica plate
(silica gel 60 F254, Merck), using hexane/ethyl acetate
(80:20, v/v, analytical grade) as mobile phases to reveal
four separate spots, referring as fraction 1 (F1), fraction
2 (F2), fraction 3 (F3) and fraction (F4).
The APH crude extract (650.2 mg) was dissolved in
ethyl acetate to induce the crystallisation of F4 from the
mixture. The crystals (15.7 mg) were filtered and dried.
The mother liquor was collected, and the solvent was re-
moved to give the thick oil (634.5 mg) which was further
purified using flash silica gel 60 column chromatography
(hexane/ethyl acetate, 80:20, v/v) to give three fractions,
F1 + F2 (392.0 mg), F3 (118.0 mg) and F4 (116.0 mg).
Preparative liquid chromatography (prep LC)
The pre-crystallisation APH crude mixture (450.0 mg)
was purified by Reveleris® prep purification system with
Reveleris® silica flash cartridge (24 g) using hexane/ethyl
acetate (80:20, v/v) as a mobile phase at flow rate of 32
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ml/min to give F1 + F2 (168.2 mg), F1 + F2 + F3 (142.3
mg), F3 (52.7 mg) and F4 (75.4 mg). The mixture of
F1 + F2 (168.2 mg) was further purified by Reveleris®
prep system using hexane/ethyl acetate (95:5, v/v) as a
mobile phase to give F1 (149.9 mg) and F2 (2.2 mg). The
mixture of F1 + F2 + F3 (20 mg) was purified by TLC
plate silica gel 60 F254, using hexane/ethyl acetate (80:
20, v/v) as a mobile phase. The band of F2 (1.2 mg) was
purely isolated.
Compound identification
Isolated compounds were structurally elucidated using
NMR, FTIR, HRMS and GC/MS techniques. The 1H
(500MHz), 13C (125MHz) and 2D NMR: COSY and
DEPT NMR spectra were recorded on a 500MHz Agi-
lent spectrometer in deuterated chloroform (CDCl3).
The FTIR analyses were performed using Nicolet 6700
FTIR spectrometer (Thermo scientific). High-resolution
mass spectra were obtained using an Agilent 6510 Q-
TOF Mass Spectrometer (ESI). The GC/MS analyses
were performed using Agilent 6870/5973n MS (EI) spec-
trometer. The peaks were identified using the mass spec-
tral library available in the software.
Fraction 1 (F1)
Rf value (TLC): 0.88 (ethyl acetate/hexane, 20:80). HRMS
(ESI): m/z 884.5865 [M]+ (calculated for C57H104O6 =
884.7833). FTIR (cm − 1): 2921.41, 2852.12 (C-H) and
1742.29 (C=O). 1H NMR δH (ppm): 5.349 (m, CH=CH),
5.264 (m, CH), 4.286 (dd, CH2), 4.151 (dd, CH2), 2.770
(t, =CH-CH2-CH=), 2.315 (t, CH2CO2), 2.042 (m,
CH2CH=CH), 1.607 (m, CH2CH2CO2), 1.254 (m, CH2)
and 0.881 (t, CH3).
13C NMR (CDCl3, 125MHz) δC
(ppm): 173.306, 173.261, 172.859 (C), 130.240, 130.039,
130.023, 129.697, 128.077, 127.910 (CH), 68.891 (CH),
62.106, 62.104 (CH2), 34.212, 34.068, 34.038, 31.940,
31.917, 31.537, 29.781, 29.720, 29.716, 29.675, 29.641,
29.625, 29.622, 29.542, 29.496, 29.375, 29.360, 29.345,
29.330, 29.288, 29.212, 29.193, 29.147, 29.136, 29.098,
29.064, 27.239, 27.213, 27.211, 27.190, 25.642, 24.898,
24.879, 24.849, 22.702, 22.694, 22.584 (CH2), 14.128,
14.082 (CH3).
Fraction 2 (F2)
Rf value (TLC): 0.61 (ethyl acetate/hexane, 20:80).
HRMS (ESI): m/z 862.6072 [M]+ (calculated for
C55H106O6 = 862.7989). FTIR (cm
− 1): 2960.97, 2913.33,
2849.18 (C-H) and 1735.55 (C=O). 1H NMR δH (ppm):
5.349 (m, CH=CH), 5.264 (m, CH), 4.282 (dd, CH2),
4.148 (dd, CH2), 2.769 (t, =CH-CH2-CH=), 2.323 (t,
CH2CO2), 2.040 (m, CH2CH=CH), 1.598 (m,
CH2CH2CO2), 1.253 (m, CH2) and 0.880 (t, CH3).
Fraction 3 (F3)
Rf value (TLC): 0.44 (ethyl acetate/hexane, 20:80).
HRMS (ESI): m/z 281.2468 [M +H]+ (calculated for
C18H33O2 = 281.2481). FTIR (cm
− 1): 2955.28, 2914.71,
2847.62 (C-H), 1699.69 (C=O), 1471.38, 1462.96 and
1429.69 (C=C). 1H NMR δH (ppm) 5.344 (m, CH=CH),
2.771 (t, =CH-CH2-CH=), 2.345 (t, CH2CO2), 2.042 (m,
CH2CH=CH), 1.631 (m, CH2CH2CO2), 1.255 (m, CH2)
and 0.880 (t, CH3).
Fraction 4 (F4)
Rf value (TLC): 0.27 (ethyl acetate/hexane, 20:80).
HRMS (ESI): m/z 395.3303 [M-H]+ (calculated for
C28H43O = 395.3314). GCMS (EI) m/z 396 [M]
+. FTIR
spectra (cm− 1) 3414.02 (O-H); 2952.17, 2928.38 and
2868.82 (C-H) and 1655.20 (C=C). 1H NMR spectra δH
(ppm): 5.575 (dd, 1H), 5.385 (m, 1H), 5.205 (m, 1H),
3.639 (m, 2H), 2.459 (ddd, 2H), 2.284 (t, 2H); the pos-
ition of this signal varied from 1.250–2.080 ppm in the
other saturated methylene and methine protons (total
18H); 1.044 (d, 3H), 0.948 (s, 3H), 0.925 (d, 3H), 0.833
(t, 6H) and 0.632 (s, 3H). 13C NMR δC (ppm): 141.351,
139.769 (C), 135.551, 131.962, 119.573, 116.273, 70.457,
55.728, 54.555, 46.244 (CH), 42.830 (C), 42.815 (CH),
40.797 (CH2), 40.418 (CH), 39.082, 38.373 (CH2), 37.026
(C), 33.085 (CH), 31.997, 28.283, 22.991, 21.110 (CH2),
21.098, 19.949, 19.642, 17.601, 16.281 and 12.047 (CH3).
Base hydrolysis of fraction 1 (F1)
Methanolic sodium hydroxide solution (0.5M, 5 mL)
was added to F1 (110 mg). The mixture was heated with
stirring at 90 °C for 10 min. The reaction was cooled in
an ice bath, then methanol (5 mL) was added. The
resulting mixture was heated at 90 °C for 10 min. Upon
cooling, the pH of the reaction mixture was adjusted to
zero by adding 1M of HCl (10 mL). The acidic solution
was extracted with dichloromethane (3 × 15 mL). The
combined extracts were dried over anhydrous sodium
sulfate and filtered. The dichloromethane was removed
under reduced pressure to give a crude product (107
mg), which was analysed by GC/MS.
Results
A.polytricha (AP) extraction
A.polytricha (AP) was sequentially extracted; first with
hexane, then with ethanol and finally with cold water.
Percentage yield by weight of each extract from the dry
weight of AP is tabulated in Table 1.
HIV-1 PR inhibitory activity of crude extracts
Crude extracts were screened at 1mg/mL against HIV-1
PR. DMSO (1%, v/v) and pepstatin (1mM) were used as
controls, which showed the percentage of inhibition at
8.07 ± 0.13 and 81.48 ± 0.76, respectively. APH exhibited
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the highest percentage of inhibitory activity of 71.07 ± 2.17,
followed by APE (43.82 ± 1.04%) and APW (14.80 ± 1.96%)
compared to vehicle control. (Fig. 1 and Table 2).
APH and APE show significant inhibition more
strongly in HIV-1 PR assay than that of APW. In
addition, APH has the most potent activity against HIV-
PR with 50% inhibitory concentration (IC50) of 0.80 ±
0.08 mg/ml (Table 2).
Cytotoxicity of APH crude extract
In vitro maximum safe concentration of APH crude ex-
tract against normal mammalian fibroblasts, the 3 T3-L1
cells were determined by MTT assay for 24 to 72 h.
APH showed no significant cytotoxicity on the fibro-
blasts when treated with a high concentration of APH,
1.00 mg/mL. In addition, all treated concentrations ex-
hibited percentage cell viability higher than 85% (Fig. 2).
In comparison, APH showed the HIV-1 PR inhibitory
activity (IC50 = 0.80 ± 0.08 mg/ml), at the concentration
slightly less than cytotoxic concentration (> 1.00 mg/ml).
These results suggest that APH could be safely used for
in vitro HIV-1 PR inhibition.
Isolation and purification of APH
TLC analysis of APH (80:20, v/v hexane: ethyl acetate)
revealed four fractions F1, F2, F3 and F4 with the
retention factor (Rf) of 0.88, 0.61, 0.44 and 0.27, respect-
ively (see Additional file 1: Figure S1). The F1, F2 and F4
were visible under UV light (254 nm) while the F3 was
detectable at a long wavelength (365 nm).
The crude APH (650.2 mg) was dissolved in ethyl acet-
ate to recrystallise out pure F4 (15.7 mg) as white nee-
dles form. The crude mixture recovered from the
mother liquor was further purified using the Reveleris®
prep purification system to give F1 (368.5 mg), F2 (25.5
mg), F3 (118mg) and the additional F4 (116.0 mg) as
summarised in Fig. 3a.
Identification of isolated compounds from APH by GC-MS
analysis
The chemical profile of APH was first analysed using
GC-MS, which showed five major compounds at a re-
tention time of 22.434, 24.795, 24.873, 25.185 and
40.771 min (Fig. 3b). The corresponding mass spectrom-
etry (EI-MS) analysis [M+] found m/z of 256.3, 280.3,
282.3, 284.3 and 396.4. The mass spectral library identi-
fied these m/z to be palmitic acid (12.02%), linoleic acid
Fig. 1 Percentage of inhibitory on HIV-1 PR activity of DMSO (1.0%, v/v), pepstatin (1 mM) and crude AP extracts (1 mg/ml). The error bars
indicate the standard error of the means. *p < 0.05 compared to vehicle control
Table 2 Percent relative inhibition and half-maximal inhibition
concentration (IC50) on HIV-1 PR activity of AP crude extracts,
pepstatin and DMSO
Sample %Relative inhibition IC50
APH 71.07 ± 2.17a 0.80 ± 0.08 mg/ml
APE 43.82 ± 1.04a n/a
APW 14.80 ± 1.96a n/a
Pepstatin 81.48 ± 0.76b 0.32 ± 0.05 mM
DMSO 8.07 ± 0.13c n/a
Samples were tested at a1 mg/ml, b1 mM and c1% (v/v). n/a Not applicable
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(23.75%), oleic acid (23.23%), stearic acid (12.20%) and
ergosterol (25.75%), respectively. Moreover, a group of
small peaks was found at retention time varies from
36.00 to 37.00 min with m/z of 376.3, indicating the
presence of anthraergostapentene (3.05%).
Quantitative analysis of chemical constituents in APH
The quantitative analysis of chemical constituents was
determined by extrapolating on the standard curve of
commercial ergosterol (see Additional file 1: Figure S2).
The results showed that at 10 mg/ml of APH was com-
posed of palmitic acid, linoleic acid, oleic acid, stearic
acid and ergosterol at concentrations of 0.733, 0.364,
0.679, 0.665 and 0.368 mg/ml, respectively (Table 3).
From the quantitative profile analysis, 10 mg of APH
crude extract yielded only 2.931 mg of total interested
compounds or 29.31% of starting material. This value in-
dicated low productivity of GC-MS analysis; some com-
pounds were lost during the analysis.
However, these results correlate with the calculation of
the percentage of compounds. There showed a ratio of
palmitic acid: linoleic acid: oleic acid: stearic acid: ergos-
terol is 1: 2: 2: 1: 2 in both percentage and quantitative
values. It is noteworthy that the APH crude extract con-
tained anthraergostapentene, which was derived from
the ergosterol. This was confirmed by the GC/MS ana-
lysis of commercial ergosterol, which also showed the
presence of anthraergostapentene with a retention time
between 36.00 and 37.00 min (m/z of 376.4).
Structure elucidation of APH isolated compounds
F1 was obtained as a pale-yellow wax. The structure of
F1 could be identified as triacylglycerol or fatty ester by
its 1H NMR signal pattern (see Additional file 1: Figure
S3). The FTIR spectrum showed absorption bands at
(cm− 1) 2921.41 and 2852.12 (C-H) and 1742.29 (C=O).
According to Chira et al. report [18], they suggested cal-
culation methods for determining vegetable oils compos-
ition using 1H NMR spectral data. The chemometric
equations were used to determine of oils composition on
four classes of fatty acids. These are linolenic acid, lino-
leic acid, monounsaturated fatty acids (oleic acid) and
saturated fatty acids (palmitic acid, stearic acid). The
chemometric calculation showed that triacylglycerol of
F1 comprised linoleic acid, monounsaturated fatty acids
and saturated fatty acids in the same proportion, which
could exist in two possible forms, as indicated in
Table 4.
To confirm the origin and composition of fatty acids,
the F1 was hydrolysed under basic conditions. Then hy-
drolysed crude product was subjected to GC-MS ana-
lysis. Gas chromatogram showed four major peaks
which are due to including palmitic acid methyl ester
(11.19%), linoleic acid methyl ester (25.27%), oleic acid
methyl ester (20.99%) and stearic acid methyl ester
(12.20%) at the retention time of 21.944, 24.259, 24.338
and 24.677, respectively. Moreover, the palmitic acid
(3.56%) and the incomplete hydrolysed product were
found in this analysis (see Additional file 2: Table S1).
These data indicated that the F1 contains two possible
forms of triacylglycerols; form A and B. Form A of triac-
ylglycerols should comprise one palmitic acid, linoleic
acid and oleic acid while form B of triacylglycerol com-
prises a stearic acid, linoleic acid and oleic acid. Two
possible combinations were derived from the observed
proportion of four fatty acids: palmitic acid, linoleic acid,
oleic acid and stearic acid in the GC-MS analysis of hy-
drolysed F1. The ratio of the four acids was found to be
1: 2: 2: 1. Due to oleic acid was classified as a monoun-
saturated fatty acid, palmitic acid and stearic acid were
Fig. 2 Cytotoxicity of APH against 3 T3-L1 cells at 24, 48 and 72 h. The error bars indicate the standard error of the means. *p < 0.05 compared to
vehicle control
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Fig. 3 APH isolation and identification. a Schematic representation of APH isolation. b Gas chromatogram of APH
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classified as saturated fatty acids, the ratio of linoleic
acid: monounsaturated fatty acid: saturated fatty acids is
1: 1: 1. These results correlated with the results from the
chemometric calculation based on 1H NMR analysis,
which was mentioned above. The two possible forms
also are supported by the abundance of these four acids
in the quantitative analysis of APH, which found the
ratio between palmitic acid, linoleic acid, oleic acid and
stearic acid to be 1: 2: 2: 1.
Furthermore, the hydrolysed F1 was analysed by 1H
NMR spectroscopy; the 1H NMR spectrum (see Add-
itional file 1: Figure S4) showed a signal of protons
responding to methyl ester at a chemical shift of 3.666
ppm. These confirmed that fatty acid methyl esters were
produced from the hydrolysis reaction and it related to
the results of the GC-MS analysis.
F2 was obtained as a yellow oil. The structure of F2
could be identified to triacylglycerol by its 1H NMR sig-
nal pattern, and protons are responding to glycerol back-
bone at δH (ppm) 5.264 (1H at β-carbon), 4.282 (2H at
α-carbon) and 4.148 (2H at α-carbon). Mass spectrum
analysis indicated that the F2 has the molecular formula
of C55H106O6; it was confirmed by HRMS (ESI) [M]
+ m/
z 862.6072 (calculated for 862.7989). According to the
molecular formula, the F2, triacylglycerol could compose
Table 3 Quantitative analysis of APH analysis by GC-MS
Compound Quantity (mg/10mg of APH) Ratio
Palmitic acid 0.364 1
Linoleic acid 0.679 2
Oleic acid 0.665 2




Table 4 Name, structure and molecular formula of constituent compounds of APH crude extract
Compound Name Structure Molecular formula
F1A Linoleoyl, oleoyl, palmitoylglycerol C55H100O6
F1B Linoleoyl, oleoyl, stearoylglycerol C57H104O6
F2 Distearoyl, palmitoylglycerol C55H106O6
F3 Linoleic acid C18H32O2
F4 Ergosterol C28H44O
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of two stearic acids and one palmitic acid unit in the
molecule (Table 4).
F3 was obtained as a pale-yellow oil. The structure of
F3 could be identified as an unsaturated fatty acid by its
1H NMR signal pattern. The 1H NMR showed peaks
responding to alkene and allylic protons at δH (ppm)
5.344 (CH=CH) and 2.771 (=CH-CH2-CH=), respect-
ively. The FTIR spectrum showed absorption bands at
(cm − 1) 2955.28, 2914.71 and 2847.62 (C-H); 1699.69
(C=O) and 1471.38, 1462.96 and 1429.69 (C=C). The
mass spectroscopy data indicated that the F3 has the
molecular formula of C18H32O2, it is supported by
HRMS (ESI) [M +H]+ m/z 281.2468 (calculated for
281.2481). All spectroscopy data indicated that the F3
was identified as linoleic acid (Table 4). F3, therefore, is
one of the hydrolysed products from F1.
F4 was obtained as a white powder. Spectroscopy data
indicated that the F4 has the molecular formula of
C28H44O; it is supported by HRMS (ESI) [M-H]
+ found
m/z 395.3303 (calculated for 395.3314). Moreover, the 1H
and 13C NMR spectra of F4 are in agreement with that re-
ported in the literature for ergosterol [19] (Table 4).
HIV-1 PR inhibitory activity of APH identified compounds
Our results have shown that all identified compounds
significantly inhibited HIV-1 PR activity. At 20 μM of
triacylglycerols (F1 and F2) and linoleic acid (F3)
inhibited HIV-1 PR activity with the percentage of
relative inhibition range from 13 to 23%. Ergosterol
(F4) was inactive against the enzyme at a concentra-
tion of ≥5 μM; however, it became significant active
at a concentration ≤ 10 μM (Fig. 4).
Discussion
In this study, we have demonstrated that hexane extract
from AP could inhibit HIV-1 replication by blocking
HIV-1 PR activity. This further supports by the work of
El-Mekkawy et al., which reported that 3β-5α-
dihydroxy-6β -methoxyergosta-7,22-diene, found in
hexane fraction of methanol extract from Ganoderma
lucidum could inhibit HIV-1 PR activity [20]. Moreover,
hexane extract of Lignosus rhinocerus showed strong in-
hibitory effect on HIV-1 PR [21]. Since AP is a common
edible mushroom, compounds presented within the
crude extract, therefore are considered to be non-toxic.
The phytochemicals that are responsible for the ob-
served inhibitory activity would be valuable compounds
for HIV-1 drug discovery. Although there have been a
few chemical constituents reported to be isolated from
AP. However, to our knowledge, a thorough investiga-
tion of phytochemicals with anti-HIV properties from
AP is not known. Hence, the investigation of the APH
crude extracts has been the main focus of this research.
Four compounds were isolated and purified from
APH. Structure elucidation of these four compounds
using NMR, IR and HRMS techniques confirmed
them to be two triacylglycerols (F1 and F2), linoleic
acid (F3) and ergosterol (F4). However, the results
from GC-MS revealed five compounds; palmitic acid,
linoleic acid (F3), oleic acid, stearic acid and ergos-
terol (F4). The GC-MS results accounted for F3 and
F4 and not for F1 and F2. One can conclude that
the presence of unaccounted fatty acids resulted
from the high temperature of GCMS that induced
hydrolysis of F1 and F2 to form their corresponding
fatty acids.
Fig. 4 Percent relative inhibition of HIV-1 PR activity of identified compounds: F1 (combination of linoleoyl, oleoyl, palmitoylglycerol and linoleoyl,
oleoyl, stearoylglycerol), F2 (distearoyl, palmitoylglycerol), F3 (linoleic acid) and F4 (ergosterol). The error bars indicate the standard error of the
means. *p < 0.05 compare to vehicle control. # p < 0.05 compared to other concentration of the same treatment
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Our finding of three triacylglycerols, linoleic acid and
ergosterol in APH is comparable to the previous studies,
which showed fungi could be a source of fatty acids and
sterol such as palmitic, stearic, oleic and linoleic acid as
well as ergosterol [22]. Ruess et al. also reported that
many edible mushroom species contain a high propor-
tion of unsaturated fatty acid, particularly linoleic acid
[23] that is also a precursor of 1-octen-3-ol; the aromatic
compound might give mushroom flavour [24].
Moreover, all identified compounds exhibited HIV-1
PR inhibition, but their activities were lower than the
original APH, suggesting that HIV-1 PR inhibitory activ-
ity of APH might result from a combined effect of these
identified compounds. Therefore, the synergistic effect
of the isolated compounds should be evaluated further
as a potential HIV-1 PR inhibitor. Further, ergosterol ap-
peared to have a limited concentration range of activity
(2.5 to 10 μM). This finding might be due to the solubil-
ity limit of ergosterol, in water. The solubility of ergos-
terol, perhaps improved when it was in the mixture of
other components of APH. These results suggest that all
identified compounds in APH, worked synergistically to
inhibit HIV-1 PR.
Previous reports found that several triterpenoids such
as oleanolic acid, uvaol, ursolic acid, maslinic acid and
2α, and 19α-dihydroxy-3-oxo-12-ursen-28-oic acid ex-
hibited anti-HIV-1 PR activity [12–14]. Lee et al. dem-
onstrated that palmitic acid, saturated fatty acid could
inhibit viral entry by directly blocking gp120-CD4 com-
plex formation [25]. In addition, linoleic acid and oleic
acid could inhibit HIV-1 RT activity in vitro determin-
ation [26]. Interestingly, linoleic acid might be a dual
HIV-1 enzymes inhibitor that could inhibit not only
HIV-1 PR but also RT.
Conclusions
In conclusion, the screening assays showed that APH
and APE inhibited both HIV-1 PR activity. APH pro-
vided the most potent inhibitory activity on HIV-1
PR. The chemical analysis revealed that APH was
composed of four significant compounds including
two triacylglycerols, linoleic acid and ergosterol. For
triacylglycerols, they comprise of four corresponding
fatty acids: palmitic acid, linoleic acid, oleic acid and
stearic acid. Quantitative of fatty acids composition
showed a higher proportion of unsaturated fatty acids
than saturated fatty acids. All identified compounds
significantly inhibited HIV-1 PR activity. These results
suggested that AP could be a good source of
therapeutic fatty acids and ergosterol, which have the
anti-HIV-1 replication. Therefore, our results have
provided useful data for an alternative approach to
HIV-1 PR drugs development.
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